Chronic use of sodium ferric gluconate complex in hemodialysis patients: Safety of higher-dose (≥250 mg) administration

American Journal of Kidney Diseases

Volumn 41, Issue 3, 2003, Pages 651-657

  Folkert, Vaughn W ^a   Michael, Beckie ^b   Agarwal, Rajiv ^b   Coyne, Daniel W ^b   Dahl, Naomi ^b   Myirski, Pamela ^b   Warnock, David G ^b  

^a Baumritter Kidney Center   (United States)

^b NONE

Author keywords

Anemia; Hemodialysis (HD); Higher doses; Intravenous iron; Iron; Iron deficiency; Iron sucrose; Safety; Sodium ferric gluconate

Indexed keywords

FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; IRON DEXTRAN;

ADULT; AGED; ARTHRALGIA; ARTICLE; CHRONIC KIDNEY DISEASE; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG SAFETY; EDEMA; FEMALE; FEVER; HEMODIALYSIS; HUMAN; IRON DEFICIENCY ANEMIA; IRON STORAGE; IRON THERAPY; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PERITONEAL DIALYSIS; PRURITUS; THORAX PAIN;

EID: 0037374639     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2003.50141     Document Type: Article

References (27)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987
2. Eschbach JW, Cook JD, Scribner BH, Finch CA: Iron balance in hemodialysis patients. Ann Intern Med 87:710-713, 1977
3. Fishbane S, Wagner J: Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis. Am J Kidney Dis 37:879-883, 2001
4. Fishbane S, Maesaka JK: Iron management in endstage renal disease. Am J Kidney Dis 29:319-333, 1997
5. Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J: Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial. Am J Kidney Dis 33:471-482, 1999
6. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50:1694-1699, 1996
7. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for anemia of chronic renal disease, 2000. Am J Kidney Dis 37:S182-S238, 2001 (supp 1)
8. Silverberg DS, Iaina A, Peer G, et al: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27:234-238, 1996
9. Locatelli F, Olivares J, Walker R, et al: Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 60:741-747, 2001
10. Silverbera DS, Blum M, Aabaria Z, et al: Intravenous iron for the treatment of predialysis anemia. Kidney Int Suppl 69:S79-85, 1999
11. Dahdah K, Patrie JT, Bolton WK: Intravenous iron dextran treatment in predialysis patients with chronic renal failure. Am J Kidney Dis 36:775-782, 2000
12. Ferrlecit® Prescribing Information, March 2001, Watson Pharma, Inc, Morristown, NJ, http://www.ferrlecit.com/ Accessed March 13, 2002
13. Michael B, Coyne DW, Fishbane S, et al: Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int 61:1830-1839, 2002
14. Nissenson AR, Strobos J: Iron deficiency in patients with renal failure. Kidney Int Suppl 69:S 18-21, 1999
15. Macdougall IC: Individualizing target haemoglobin concentrations - Tailoring treatment for renal anaemia. Nephrol Dial Transplant 16:9-14, 2001 (suppl 7)
16. Ahsan N: Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: A prospective, cross-over trial. Adv Perit Dial 16:80-84, 2000
17. Faich G, Strobos J: Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 33:464-470, 1999
18. Fletes R, Lazarus JM, Gage J, Chertow GM: Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 37:743-749, 2001
19. Horl WH: Should we still use iron dextran in hemodialysis patients? Am J Kidney Dis 37:859-861, 2001
20. Kosch M, Bahner U, Bettger H, Matkies F, Teschner M, Schaefer RM: A randomized controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs. iron gluconate (Ferrlecit) in hemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 16:1239-1244, 2001
21. Prakash S, Walele A, Dimkovic N, Bargman J, Vas S, Oreopoulos D: Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients. Perit Dial Int 21:290-295, 2001
22. Stoves J, Inglis H, Newstead CG: A randomized study of oral vs. intravenous supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 16:967-974, 2001
23. Chandler G, Harchowal J, Macdougall IC: Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 38:988-991, 2001
24. Sunder-Plassmann G, Horl WH: Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 11:1797-1802, 1996
25. Javier AM, Arruda JAL, Lash JP: "High dose" sodium ferric gluconate (Ferrlecit) is safe and effective in peritoneal dialysis patients. Nephrol Nurs J 29:183-186, 2002
26. Danielson BG, Salmonson T, Derendorf H, Geisser P: Pharmacokinetics of iron (III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung 46:615-621, 1996
27. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K: Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. ironsaccharate administration. Nephrol Dial Transplant 15:1827-1834, 2000